AstraZeneca's New Lung Treatment Could Become Market Leader
Dow Jones
Sep 03
1210 GMT - AstraZeneca's new drug for chronic obstructive pulmonary disease could become a market leader if it proves to be effective across all patient groups, Berenberg analysts say in a research note. Initial trial results released by the U.K. drugmaker earlier this year showed the drug, tozorakimab, delivered benefits both in the primary population of former smokers and in the overall population, and across stages of lung function, the analysts say. Similar drugs from Roche and Sanofi delivered mixed results in trials last year, but AstraZeneca's is expected to work across a broader cohort of COPD patients, they add. "We would view 30% exacerbation reduction to be a highly positive result and ahead of expectations," Berenberg says. Shares rise 1.5%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.